The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

Among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

Anker said that additional research is needed to determine whether intravenous iron supplementation also brings benefits for people with heart failure with preserved ejection fraction, a different ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...